trimetrexate has been researched along with Cancer of Cervix in 1 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Weiss, GR | 1 |
| Liu, PY | 1 |
| O'Sullivan, J | 1 |
| Alberts, DS | 1 |
| Brown, TD | 1 |
| Neefe, JR | 1 |
| Hutchins, LF | 1 |
1 trial available for trimetrexate and Cancer of Cervix
| Article | Year |
|---|---|
A randomized phase II trial of trimetrexate or didemnin B for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix: a Southwest Oncology Group trial.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Depsipeptides; Female; Humans; Neoplasm Recurrence, | 1992 |